Associate Professor of Medicine, Vanderbilt University
Oncology
Dr. William Pao, MD
|
|
Give Review
William practices Oncology. He researched medicine at Yale University School of Medicine. Yale University School of Medicine is one of the top medical schools in the US. Yale University School of Medicine is ranked 7 in research and 57 in primary care medicine He received 1 awards: "Elected Member". William has written publications. He has 29 publications published with PubMed. The lastest publication is: 'CUSTOM-SEQ: A Prototype for Oncology Rapid Learning in a Comprehensive EHR Environment.' He accepts Medicare.
Publications
- Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung Cancer.
- Anchored multiplex PCR for targeted next-generation sequencing.
- Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung Cancer.
- Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation...
- Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies.
- Characterization of breast Cancers with PI3K mutations in an academic practice setting using SNaPshot profiling.
- Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC.
- Mechanism for activation of mutated epidermal growth factor receptors in lung Cancer.
- Targeted therapies: Afatinib-new therapy option for EGFR-mutant lung Cancer.
- Application of next generation sequencing to human gene fusion detection: computational tools, features and perspectives.
- DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): A Catalog of Clinically Relevant Cancer Mutations to Enable Genome-Directed AntiCancer Therapy.
- Complications of targeted drug therapies for solid Malignancies: manifestations and mechanisms.
- Consensus rules in variant detection from next-generation sequencing data.
- NGS catalog: A database of next generation sequencing studies in humans.
- Routine multiplex mutational profiling of Melanomas enables enrollment in genotype-driven therapeutic trials.
- Frequency of driver mutations in Lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.
- A new target for therapy in squamous cell carcinoma of the Lung.
- Morphologic features of adenocarcinoma of the Lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.
- Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients.
- Insights into ALK-driven Cancers revealed through development of novel ALK tyrosine kinase inhibitors.
- EGFR-Mutant Lung Adenocarcinomas Treated First-Line with the Novel EGFR Inhibitor, XL647, Can Subsequently Retain Moderate Sensitivity to Erlotinib.
- Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains.
- A phase II trial of Salirasib in patients with Lung adenocarcinomas with KRAS mutations.
- EGFR mutant Lung adenocarcinomas in patients with germline BRCA mutations.
- BAC consensus conference, November 4-6, 2004: epidemiology, pathogenesis, and preclinical models.
- Monitoring EGFR-mutant lung Cancers by means of the blood.
- T4 or MI?
- CUSTOM-SEQ: A Prototype for Oncology Rapid Learning in a Comprehensive EHR Environment.
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Elected Member
Education
-
Memorial Sloan-Kettering Cancer Center -
New York Presbyterian Hospital -
Yale University School of Medicine
Hospital
-
Vanderbilt Hospital and Clinics
Drug Facts
| NPI NUMBER | 1700857604 | |
| NPPES Provider LastName | PAO | |
| NPPES Provider FirstName | WILLIAM | |
| NPPES Provider ZIPCode | 372320021 | |
| NPPES Provider State | TN | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 179.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 31.0 | |
| Percent Opioid Claims | 17.32 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1700857604 |
| Last Name Of The Provider | PAO |
| First Name Of The Provider | WILLIAM |
| View All |
Similar Doctors
|
Dr. Michel E. Kuzur, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Jordan D. Berlin, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Igor Puzanov, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Jeffrey R. Infante, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
Dr. Leora Horn, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Carlos L. Arteaga, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
Dr. Vandana G. Abramson, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
Dr. Kent C. Shih, MD
This Doctor is OpenDoctor Recommended.
|